**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 56538

**Manuscript Type:** CASE REPORT

**COVID-19 in a liver transplant recipient: Could iatrogenic immunosuppression have prevented severe pneumonia? A case report**

Sessa A*et al*. COVID-19 in a liver-recipient and immunosuppression management

Anna Sessa, Alessandra Mazzola, Chetana Lim, Mohammed Atif, Juliana Pappatella, Valerie Pourcher, Olivier Scatton, Filomena Conti

**Anna Sessa,** Department of Hepatology and Gastroenterology, University of Naples Federico II, Napoli 80131, Italy

**Anna Sessa, Alessandra Mazzola, Juliana Pappatella, Filomena Conti,** APHP, Unité Médicale de Transplantation Hépatique Hôpital Pitié Salpêtrière, Paris 75013, France

**Alessandra Mazzola, Olivier Scatton, Filomena Conti,** Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine (CRSA), Paris 75013, France

**Chetana Lim, Olivier Scatton,** APHP, Unité de Chirurgie Hépatobiliaire et Transplantation Hépatique, Hôpital Pitié Salpêtrière, Paris 75013, France

**Mohammed Atif,** APHP, Centre d’immunologie et des Maladies Infectieuses, Inserm U1135, Hôpital Pitié-Salpêtrière, Paris 75013, France

**Juliana Pappatella,** Hospital Felicio Rocho, Barro Preto 9530, Brazil

**Valerie Pourcher,** APHP, Service des Maladies Infectieuses, Hôpital Pitié Salpêtrière, Paris 75013, France

**Filomena Conti,** Sorbonne Université, INSERM, Institute of Cardiometabolisme and Nutrition (ICAN), Paris 75013, France

**Author contributions:** Sessa A and Mazzola A were the patient’s doctors, reviewed the literature and contributed to manuscript drafting; Pourcher V performed the infectious diseases consultation, and drafted the manuscript; Lim C performed the surgery consultation; Pappatella J contributed to manuscript drafting; Scatton O, Conti F and Atif M were responsible for the revision of the manuscript for important intellectual content; and all authors issued final approval for the version to be submitted.

**Corresponding author: Alessandra Mazzola, MD, PhD, Doctor,** APHP, Unité Médicale de Transplantation Hépatique Hôpital Pitié Salpêtrière, Boulevard de l’Hôpital 47-83, Paris 75013, France. alessandra.mazzola3@gmail.com

**Received:** May 5, 2020

**Revised:** May 22, 2020

**Accepted:** October 26, 2020

**Published online:**

**Abstract**

BACKGROUND

Coronavirus disease (COVID) is a new and highly contagious infectious disease caused by the coronavirus (COVID-19 or severe acute respiratory syndrome coronavirus 2). There is limited data regarding the incidence and management of COVID-19 in immunocompromised patients’ post-transplantation. In the pre-COVID-19 era, these patients were already at an increased risk of developing opportunistic infections. These often manifested with atypical symptoms.

CASE SUMMARY

We report another case of uneventful COVID-19 pneumonia in a 58-year old male who was 18 mo’ post liver transplantation. He received tacrolimus monotherapy since July 2019. The clinical manifestations included only epigastric pain radiating to the right hypochondrium, nausea and vomiting. He had no fevers, cough, shortness of breath, anosmia or dysgeusia even if the chest computed tomography scan revealed an extension of the multiple patchy ground-glass density shadows to the upper lobe of the left lung too. He was hospitalised and received a course of oral chloroquine (200 mg × 3 per day) for a period of 10 d. Interestingly, the COVID 19 infection was uneventful though there were no modifications to his tacrolimus dosing. He was successfully discharged. We performed subsequent follow-up *via* telemedicine.

CONCLUSION

In light of the current pandemic, it is even more important to identify how the liver recipient’s patients present and are managed, especially for immunosuppression treatment.

**Key Words:** Liver transplantation; COVID-19; Immunosuppression; Gastrointestinal symptom; Infection; Case report

Sessa A, Mazzola A, Lim C, Atif M, Pappatella J, Pourcher V, Scatton O, Conti F. COVID-19 in a liver transplant recipient: Could iatrogenic immunosuppression have prevented severe pneumonia? A case report. *World J Gastroenterol* 2020; In press

**Core Tip:** Coronavirus disease (COVID) is a novel and unknown infectious disease that involves all the world due to a novel coronavirus (named severe acute respiratory syndrome coronavirus 2 latter). Immunocompromised patients often present atypical presentations of viral diseases. We report a case of a COVID-19 infection in a liver transplant recipient, in which the first clinical symptoms were abdominal pain without fever or respiratory symptoms. The immunosuppression seems to be doesn’t worsen the prognostic of COVID-19 pneumonia for this patient but future studies including more patients are needed to explore the impact of COVID-19 infections in this special setting.

**INTRODUCTION**

Coronavirus disease 2019 (COVID-19) is a highly infectious viral disease with over 3 million confirmed cases globally and over 200000 deaths. On the 30th of January 2020, the World Health Organization declared the Chinese outbreak of COVID-19 as a “Public Health Emergency of International Concern”. To contain COVID-19, their Emergency Committee recommended the need for early detection, isolation, contact tracing as well as prompt treatment. However, despite rigorous efforts by governments globally to contain this virus, its incidence continues to rise[1].

Solid organ transplant (SOT) recipients are under chronic immunosuppression and thus, at an increased risk of developing opportunistic infectious diseases. Amongst SOT patients, the early clinical reports of COVID-19 have been limited to heart and kidney transplant recipients only. In this report, we describe the management of COVID-19 infection in a liver transplantation (LT) recipient[2].

**CASE PRESENTATION**

***Chief complaints***

A 58-year old black male who was 18 mo’ post LT presented to our Emergency Department with abdominal pain.

***History of present illness***

On the 9th of March, he developed epigastric pain radiating to the right hypochondrium as well as nausea and vomiting. He had no fevers, cough, shortness of breath, anosmia or dysgeusia.

***History of past illness***

The liver transplant had been performed in July 2018 for hepatocellular carcinoma and end-stage liver disease secondary to hepatitis B (HBV). He was on tacrolimus-based immunosuppression in mono-therapy since July 2019 and took a nucleoside analogue for HBV graft reinfection prophylaxis. He had stopped mycophenolate mofetil because of repetitive urinary infections.

Unfortunately, this gentleman’s early and late post-transplant course was complicated by the need for further surgical and endoscopic interventions. In November 2018, he underwent emergency laparotomy for adhesional bowel obstruction during which a colostomy was formed. In January 2019, he presented with repetitive cholangitis and iatrogenic acute pancreatitis. This was related to issues with biliary drainage and thus, was resolved after undergoing an endoscopic retrograde cholangio-pancreatography.

In terms of other relevant medical history, he took aspirin as thromboprophylaxis for prevention of hepatic artery thrombosis and was on amlodipine for arterial hypertension. He denied any history of recent foreign travel or exposure to others infected/suspected of COVID-19.

***Personal and family history***

The patient did not smoke or consume alcohol. There was no noteworthy family medical history.

***Physical examination***

His physical examination was unremarkable.

***Laboratory examinations***

On the 10th of March, his laboratory results revealed; low lymphocyte count, percentage of lymphocytes and a slightly increased C-reactive protein (CRP) at (12.4 mg/L). There were no other abnormalities identified (Table 1).

***Imaging examinations***

His abdominal computed tomography (CT) scan with contrast was unremarkable from the abdominal perspective however, the lower chest slices identified multiple bilateral patchy ground-glass density shadows. For this reason, the 12th of March, he underwent a formal chest CT scan, which revealed an extension of the multiple patchy ground-glass density shadows to the upper lobe of the left lung too (Figure 1). All of this was suggestive of COVID-19 pneumonia and the patient was hospitalised in infectious disease department of our hospital the same day.

***Further diagnosis work-up***

At admission, he remained afebrile and his clinical observations such as blood pressure, pulse, blood oxygen saturation (98%) were all within normal ranges. The body mass index was 22 kg/m2. He thus did not require intensive support neither oxygen therapy. On examination of his chest, there were no positive cardiac- or pulmonary-related findings. However, upon abdominal examination, he continued to have epigastric pain radiating to the right hypochondrium.

His laboratory results revealed an exacerbation of the lymphocyte counts and percentages as well as an increase in his CRP (112.28 mg/L) (Table 1). There were no abnormalities in his liver and kidney biochemical markers. In terms of confirming COVID-19, his nasopharyngeal and oropharyngeal swab specimens came back as positive using the real-time polymerase chain reaction.

**FINAL DIAGNOSIS**

The radiological and virological characteristics were strongly suggestive for COVID-19 pneumonia with gastrointestinal involvement in a LT patient.

**TREATMENT**

On the 16th March, he received a course of oral chloroquine (200 mg × 3 per day) for a period of 10 d. No antibiotic treatment was administered. We made no modifications to his tacrolimus dosing (serum level was 3.8 ng/mL).

**OUTCOME AND FOLLOW-UP**

He was successfully discharged to advice to finish his course of chloroquine at home and self-isolate. We performed subsequent follow-up *via* telemedicine. At the end of his treatment, his abdominal pain had resolved and his laboratory results were normal too (Table 1). After two months of COVID infection, no clinical and biological abnormalities have been found during our medical consultation.

**DISCUSSION**

There remains limited knowledge of the impact of COVID-19 in SOT patients. It is all the more challenging for LT as recent case reports have been limited to kidney and heart recipients only[3-5]. In a previous manuscript, Qin *et al*[6] described the diagnose of COVID-19 in a LT-recipient during the peri-operative period. This was put down to an unrecognized infection caught pre-transplantation.Also, few cases are recently reported in Lombardia transplant centre, in a Spanish series of SOT and in a Chinese report for a total number of 7 patients[7-9]. The clinical characteristics and outcomes of COVID-19 LT patients are summarized in Table 2. To our knowledge, our report is another case of COVID-19 infection in a patient after 2 years of LT.

***Symptoms***

Infections might be considered in the differential diagnosis in the case of changes in clinical status of SOT even in the absence of common signs or symptoms of infection. Data showed that, fever and physical signs of all types of infection in SOT patients, especially pulmonary and gastrointestinal infections, are diminished with subtle laboratory or radiological signs[10].

For symptoms of COVID-19 infection, it seems that SOT patients consistently have atypical presentations.

Our patient had epigastric pain, nausea and vomiting without any symptoms classically associated with COVID-19. A recent manuscript regarding COVID-19 infection in a heart transplant recipient reported that their patient presented with fever, diarrhoea, fatigue but no respiratory symptoms[3]. Also, in the Spanish case series, the authors reported 6 cases in liver transplant recipients: Five of them presented with respiratory symptoms, one presented with only diarrhoea[8].

Interestingly, a different report in a patient post-kidney transplantation described that their patient presented with conjunctivitis. Although this could be because the virus is present in conjunctival secretions, < 1% of other COVID-19 patients present in this manner[5].

In terms of explaining the modality of our patients’ gastrointestinal symptoms, these could be due to the presence of the angiotensin-converting enzyme II (ACE2) receptors in the upper oesophagus (stratified squamous epithelium) and intestinal enterocytes. The ACE2 receptor is the entry mechanism for the severe acute respiratory syndrome coronavirus (SARS-CoV) virus into human cells. This receptor is also highly expressed in alveolar type II pneumocytes, which may the development of respiratory symptoms classically associated with COVID-19 infection. Upon intracellular entry, the host transmembrane serine protease enzyme (TMPRSS) helps to release the viral proteins into the cell. It is plausible that the presence of the ACE2 receptors on the gastrointestinal cells may explain the occurrence of abdominal pain and diarrhoea[11]. The SARS-CoV-2 virus has been found in faeces and stool samples even when it is no longer detectable in the respiratory tract. This suggests the possibility of a faecal–oral route of viral transmission[12].

***Immunosuppression management***

The risk of serious infections in SOT is determined by interactions between the patient’s epidemiological exposures and the state of immune suppression. In case of infection, the reduction in immunosuppression may be a useful component of antimicrobial therapy but with an increased risk of graft rejection or immune reconstitution syndromes. Reduction in specific immunosuppressive regimen should be roughly linked to the host responses desired for the pathogens encountered (*e.g.*, steroids for bacteria and fungi, calcineurin inhibitors for viruses, cell cycle agents in neutropenia) recognizing that each agent has multiple effects on the immune system[10].

In our case, instead, our decision to continue tacrolimus at the same dose was based upon recommendations from The French Society of Transplantation as well as the recent joint position paper by The European Society for Study of Liver (EASL) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID)[13,14]. The French guidelines recommended that LT recipients who were more than a year post-transplant to make the following modifications to their immunosuppression regimens[13]: (1) Patients on dual therapy of tacrolimus/mycophenolate plus mammalian transporter of rapamycin (mTOR) inhibitor: Maintain the tacrolimus/mycophenolate, however discontinue the mTOR inhibitor; and (2) Patients on monotherapy with mycophenolate acid or mTOR inhibitor: Maintain the same treatment at the same dose.

In parallel, the EASL-ESCMID recommendation was to only reduce immunosuppression dosage under special circumstances (*e.g.*, drug-induced lymphopenia, or bacterial/fungal superinfection in the case of severe COVID-19)[14]. Furthermore, the safety of immunosuppression therapy was confirmed in a recent case series from Italy, in which immunosuppression seemed not to increased risk of severe pulmonary disease in children who had received liver transplants, compared with the general population[15]. In comparison with Lombardia experience, and in line with Spanish experience, no change in immunosuppression therapy was done[7,8]. Although our patient neither stopped nor reduced immunosuppression, they had a favourable outcome using an experimental treatment.In conclusion, it seems reasonable that all these decisions were to be made in close consultation with the patients’ local transplant hepatologist[14].

Overall, there is limited data regarding immunosuppression management in COVID-19-positive transplant patients. In these patients, it is critical to get the right balance between protecting the allograft as well as aiding the immune system in mounting an effective anti-COVID-19 response. Moreover, it is most concerning that a subgroup of non-transplant patients with severe COVID-19 have been shown to develop a cytokine storm-like syndrome involving haemophagocytic lymphohistiocytosis and multi-organ failure[16]. The authors who identified this suggested that all patients with severe COVID-19 should be screened for hyperinflammation to identify the subgroup for whom immunosuppression could prevent mortality[16].This is amongst one of the primary reasons for which clinical trials are underway to test a broad range of anti-inflammatory agents (*e.g.*, steroids, intravenous immunoglobulins, anti-IL-1, anti-IL-6, and JAK inhibition)[17,18]. In the case of our patient, we would speculate that the continued use of tacrolimus in our patient could have in parallel, also protected against the cytokine storm syndrome.

***Treatment of COVID-19 pneumonia and outcomes***

When infections occur in SOT were associated with an increased risk of morbidity and mortality especially in the first three months after transplantation[10]. A rapid diagnosis and the beginning of a specific therapy consent an improvement in a clinical outcome.

Our patient received a 10-d course of chloroquine rapidly after diagnosis with no reported side effects. However, it is important to consider that there is currently no global consensus on the ideal treatment for COVID-19 infection in transplant and non-transplant patients. It is all the most challenging in transplantation as we generally have a lower threshold to treat other opportunistic infections.

An early clinical trial from China conducted in COVID-19-positive non-transplant patients demonstrated that chloroquine had a significant effect, both in terms of clinical outcome and viral clearance. Indeed, the Chinese guidance recommends the use of chloroquine as a treatment for COVID-19 pneumonia regardless of severity[19,20]. Furthermore, a recent French trial conducted reported the efficacy of hydroxychloroquine treatment in reduction and suppression of viral load for COVID-19 patients[21]. In our case, it is theoretically plausible that, although chloroquine could have reduced viral load, the concomitant tacrolimus inhibited the inflammatory cascade involved in the propagation of severe respiratory symptoms[22].

Moreover, few data are available regarding the outcomes on COVID-19 liver transplant patients. As reported in Table 2, three of among 111 patients liver transplant survivors (transplanted more than 10 years ago) died following severe COVID-19 disease[7], 3 patients died in a Spanish series and, a fatal case of COVID pneumonia after 3 years of LT in a 59 old man with probably overlap chronic rejection was reported by Huang *et al*[9] Although the favourable outcome of our patient find another explanation also in scarce presence of metabolic-related comorbidities (only arterial hypertension), normally increased with time since transplant[2,23], that might be associated with an increased risk of severe COVID-19 disease.

**CONCLUSION**

To our knowledge, this is one of few uneventful reports about COVID-19 infection in a patient post-LT. He had atypical symptoms which successfully resolved with chloroquine treatment and continued tacrolimus. We would recommend that screening for underlying COVID-19 infection be performed in all immunocompromised patients presenting with atypical symptoms. The recommendations from the national guidance should been modified with the evolution of our understanding of this disease and its treatment.

**REFERENCES**

1 **World Health Organization**. Coronavirus disease 2019 (COVID-19) Situation Report – 44. 2020 Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200304-sitrep-44-covid-19.pdf?sfvrsn=93937f92\_6

2 **Huang C**, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; **395**: 497-506 [PMID: 31986264 DOI: 10.1016/S0140-6736(20)30183-5]

3 **Li F,** Cai J, Dong N. First cases of COVID-19 in heart transplantation from China. *J Heart Lung Transplant* 2020; **39**: 496-497 [PMID: 32362394 DOI: 10.1016/j.healun.2020.03.006]

4 **Zhu L**, Xu X, Ma K, Yang J, Guan H, Chen S, Chen Z, Chen G. Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression. *Am J Transplant* 2020; **20**: 1859-1863 [PMID: 32181990 DOI: 10.1111/ajt.15869]

5 **Guillen E**, Pineiro GJ, Revuelta I, Rodriguez D, Bodro M, Moreno A, Campistol JM, Diekmann F, Ventura-Aguiar P. Case report of COVID-19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation? *Am J Transplant* 2020; **20**: 1875-1878 [PMID: 32198834 DOI: 10.1111/ajt.15874]

6 **Qin J**, Wang H, Qin X, Zhang P, Zhu L, Cai J, Yuan Y, Li H. Perioperative Presentation of COVID-19 Disease in a Liver Transplant Recipient. *Hepatology* 2020; Online ahead of print [PMID: 32220017 DOI: 10.1002/hep.31257]

7 **Bhoori S**, Rossi RE, Citterio D, Mazzaferro V. COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy. *Lancet Gastroenterol Hepatol* 2020; **5**: 532-533 [PMID: 32278366 DOI: 10.1016/S2468-1253(20)30116-3]

8 **Fernández-Ruiz M**, Andrés A, Loinaz C, Delgado JF, López-Medrano F, San Juan R, González E, Polanco N, Folgueira MD, Lalueza A, Lumbreras C, Aguado JM. COVID-19 in solid organ transplant recipients: A single-center case series from Spain. *Am J Transplant* 2020; **20**: 1849-1858 [PMID: 32301155 DOI: 10.1111/ajt.15929]

9 **Huang JF**, Zheng KI, George J, Gao HN, Wei RN, Yan HD, Zheng MH. Fatal outcome in a liver transplant recipient with COVID-19. *Am J Transplant* 2020; **20**: 1907-1910 [PMID: 32277591 DOI: 10.1111/ajt.15909]

10 **Fishman JA**. Infection in Organ Transplantation. *Am J Transplant* 2017; **17**: 856-879 [PMID: 28117944 DOI: 10.1111/ajt.14208]

11 **Gu J**, Han B, Wang J. COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission. *Gastroenterology* 2020; **158**: 1518-1519 [PMID: 32142785 DOI: 10.1053/j.gastro.2020.02.054]

12 **Ianiro G**, Mullish BH, Kelly CR, Sokol H, Kassam Z, Ng SC, Fischer M, Allegretti JR, Masucci L, Zhang F, Keller J, Sanguinetti M, Costello SP, Tilg H, Gasbarrini A, Cammarota G. Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel. *Lancet Gastroenterol Hepatol* 2020; **5**: 430-432 [PMID: 32192627 DOI: 10.1016/S2468-1253(20)30082-0]

13 **Société Francophone de Transplantation (SFT);** Société Francophone de Néphrologie**,** Dialyse et Transplantation (SFNDT); Groupe Infection et Immunodépression, Société de pathologie infectieuse de langue française (SPILF). Prise en charge de l’infection due au SARS-CoV-2 chez les patients adultes transplantés d’organe solide. Available from: https://content.tts.org/content/covid19/COVID19\_et\_transplantees\_d\_organes\_solides\_Guide\_pratiquev1\_SFT\_SFNDT\_SP.pdf

14 **Boettler T**, Newsome PN, Mondelli MU, Maticic M, Cordero E, Cornberg M, Berg T. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. *JHEP Rep* 2020; **2**: 100113 [PMID: 32289115 DOI: 10.1016/j.jhepr.2020.100113]

15 **D'Antiga L**. Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic. *Liver Transpl* 2020; **26**: 832-834 [PMID: 32196933 DOI: 10.1002/lt.25756]

16 **Mehta P**, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet* 2020; **395**: 1033-1034 [PMID: 32192578 DOI: 10.1016/S0140-6736(20)30628-0]

17 **Shakoory B**, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, Cron RQ, Opal SM. Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial. *Crit Care Med* 2016; **44**: 275-281 [PMID: 26584195 DOI: 10.1097/CCM.0000000000001402]

18 **Wang DS,** Xu XL.A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). [accessed March 6, 2020]. In: Chinese Clinical Trial Registry [Internet]. Available from: http://www.chictr.org.cn/showprojen.aspx?proj=49409 Registration number: ChiCTR2000029765

19 **Gao J**, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. *Biosci Trends* 2020; **14**: 72-73 [PMID: 32074550 DOI: 10.5582/bst.2020.01047]

20 Chinese Clinical Trial Registry. Available from: http://www.chictr.org.cn/searchprojen.aspx?title=&officialname=%E6%B0%AF%E5%96%B9&subjectid=&secondaryid=&applier=&studyleader=&ethicalcommitteesanction=&sponsor=&studyailment=&studyailmentcode=&studytype=0&studystage=0&studydesign=0&minstudyexecutetime=&maxstudyexecutetime=&recruitmentstatus=0&gender=0&agreetosign=&secsponsor=&regno=&regstatus=0&country=&province=&city=&institution=&institutionlevel=&measure=&intercode=&sourceofspends=&createyear=0&isuploadrf=&whetherpublic=&btngo=btn&verifycode=&page=1

21 **Gautret P**, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Tissot Dupont H, Honoré S, Colson P, Chabrière E, La Scola B, Rolain JM, Brouqui P, Raoult D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int J Antimicrob Agents* 2020; **56**: 105949 [PMID: 32205204 DOI: 10.1016/j.ijantimicag.2020.105949]

22 **Wang M**, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res* 2020; **30**: 269-271 [PMID: 32020029 DOI: 10.1038/s41422-020-0282-0]

23 **Grasselli G**, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, Cereda D, Coluccello A, Foti G, Fumagalli R, Iotti G, Latronico N, Lorini L, Merler S, Natalini G, Piatti A, Ranieri MV, Scandroglio AM, Storti E, Cecconi M, Pesenti A; COVID-19 Lombardy ICU Network. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *JAMA* 2020; **323**: 1574-1581 [PMID: 32250385 DOI: 10.1001/jama.2020.5394]

**Footnotes**

**Informed consent statement:** Informed written consent was obtained from the patient for publication of this report and any accompanying images.

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest**.**

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** May 5, 2020

**First decision:** May 15, 2020

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** France

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Vetrugno L, Zhang HW **S-Editor:** Huang P **L-Editor: P-Editor:**

**Figure Legends**



**Figure 1 Chest computed tomography of a 58-year-old man who underwent liver transplantation in 2018.** A-C: Normal chest computed tomography (CT) of the patient in November 2019; D and E: Chest CT on admission in March 2020 showing ground-glass opacities with a peripheral distribution.

**Table 1 Laboratory tests of patients**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **No symptoms** | **Start symptoms** | **Start treatment** | **After treatment** |
| Laboratory parameters | February 22 | March 10 | March 16 | March 24 |
| AST, UI/L | 24 | 22 | 32 | 26 |
| ALT, UI/L | 19 | 28 | 16 | 24 |
| Total bilirubin (µmol/L) | 6.5 | 3.5 | 8 | 8 |
| Albumin (g/L) | 33 | 35 | 33 | 31 |
| Creatinine (µmol/L) | 118.6 | 119 | 135 | 134.5 |
| Hemoglobin (g/L) | 12.1 | 12.5 | 12.5 | 11.7 |
| Platelet | 159000 | 122000 | 136000 | 296000 |
| Lymphocytes | 1020 | 1050 | 390 | 996 |
| PT (%) | 100 | 86 | 27 | 88 |
| INR | 1 | 1.05 | 1.5 | 1.1 |
| Tacrolimus (ng/mL) | 3.5 | 3.5 | 3.2 | 3.8 |
| CRP (mg/L)  | 3.05 | 12.4 | 112.28 | 6.6 |

AST: Aspartate transaminase; ALT: Alanine transaminase; PT: Prothrombin time; INR: International normalized ratio; CRP: C reactive protein.

**Table 2 Clinical and biological characteristics of patients with coronavirus disease 2019 pneumonia after liver transplanta**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Study type** | **Patients (*n*)** | **Age (yr)** | **Time from transplantation** | **Clinical manifestations** | **Immunosuppression treatment** | **Immuno-suppression, modification** | **Metabolic comorbidities** | **Death** |
| Fernández-Ruiz *et al*[8] | Case series | 6 | 63 | 7.9 yr | Fever, shortness of breath, cough | EVE | Yes | Hypertension, diabetes | No |
| 72 | 5.5 yr | Fever, shortness of breath, cough | MMF, EVE | Yes | Hypertension, diabetes, obesity | Yes |
| 79 | 15.3 yr | Shortness of breath, cough, malaise, diarrhea | Prednisone AZA, EVE | Yes | Diabetes, chronic renal failure | Yes |
| 73 | 16.4 yr | Fever, shortness of breath, cough, malaise | MMF | Yes | Diabetes | Yes |
| 76 | 26.5 yr | Fever, thoracic, pain | Tacrolimus | No | Hypertension | No |
| 46 | 6.4 yr | Diarrhea | Tacrolimus | No |  | No |
| Bhoori *et al*[7] | Correspondence | 6 | > 65 | > 10 yr |  |  | Yes |  | Yes |
| > 65 | > 10 yr |  |  | Yes | Diabetes,overweight, hyperlipidemia | Yes |
| > 65 | > 10 yr |  |  | Yes | Diabetes,overweight, hyperlipidemia | Yes |
|  | < 2 yr |  | Calcineurin inhibitors | Yes | Diabetes,overweight, hyperlipidemia | No |
|  | < 2 yr |  | Calcineurin inhibitors | Yes |  | No |
|  | < 2 yr |  | Calcineurin inhibitors | Yes |  | No |
| Huang *et al*[9] | Case report | 1 | 59 | 3 yr | Fever, cough, chills, fatigue, icterus and diarrhea | MMF et tacrolimus |  |  | Yes |
| Qin *et al*[6] | Case report | 1 | 37 | 53 d | Persistent fever | Tacrolimus and glucocorticoids |  |  | No |

EVE: Everolimus; MMF: Mycophenolate mofetil; AZA: Azathioprine.